BR0316305A - Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit - Google Patents
Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kitInfo
- Publication number
- BR0316305A BR0316305A BR0316305-9A BR0316305A BR0316305A BR 0316305 A BR0316305 A BR 0316305A BR 0316305 A BR0316305 A BR 0316305A BR 0316305 A BR0316305 A BR 0316305A
- Authority
- BR
- Brazil
- Prior art keywords
- animal
- composition
- compound
- treating
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 206010012735 Diarrhoea Diseases 0.000 title abstract 3
- 102000003840 Opioid Receptors Human genes 0.000 title abstract 3
- 108090000137 Opioid Receptors Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000004936 stimulating effect Effects 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 2
- -1 4-Tetrazolyl-4-phenylpiperidine Compound Chemical class 0.000 abstract 3
- OGPKTRWLBLRODW-UHFFFAOYSA-N 4-phenyl-4-(2h-tetrazol-5-yl)piperidine Chemical class C1CNCCC1(C=1C=CC=CC=1)C1=NNN=N1 OGPKTRWLBLRODW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Abstract
"COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, MéTODOS PARA TRATAR A DOR EM UM ANIMAL, PARA ESTIMULAR A FUNçãO DO RECEPTOR OPIóIDE EM UMA CéLULA, PARA PREPARAR UMA COMPOSIçãO, E PARA TRATAR DIARRéIA EM UM ANIMAL, COMPOSIçãO, E KIT". Compostos 4-Tetrazolil-4-fenilpiperidina, composições que compreendem uma quantidade eficaz de um Composto 4-Tetrazolil-4fenilpiperidina, métodos para o tratamento ou a prevenção de dor ou diarréia em um animal, que compreendem administrar a um animal, que tenha necessidade do mesmo, uma quantidade eficaz de um Composto 4-Tetrazolil4-fenilpiperidina. Composto e métodos para estimular uma função de um receptor opióide em uma célula, que compreende contatar uma célula capaz de expressar um receptor opióide com uma quantidade eficaz de um Composto 4-tetrazolil- 4-fenilpiperidina, são expostos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42738102P | 2002-11-18 | 2002-11-18 | |
US46027803P | 2003-04-03 | 2003-04-03 | |
US48848803P | 2003-07-17 | 2003-07-17 | |
US10/714,066 US7202259B2 (en) | 2002-11-18 | 2003-11-13 | Therapeutic agents useful for treating pain |
PCT/US2003/036742 WO2004046132A1 (en) | 2002-11-18 | 2003-11-17 | 4-tetrazolyl-4phenylpiperidine derivatives for treating pain |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0316305A true BR0316305A (pt) | 2005-09-27 |
Family
ID=32777221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0316305-9A BR0316305A (pt) | 2002-11-18 | 2003-11-17 | Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit |
Country Status (37)
Country | Link |
---|---|
US (3) | US7202259B2 (pt) |
EP (2) | EP1562932B9 (pt) |
JP (2) | JP4601429B2 (pt) |
KR (1) | KR20050115221A (pt) |
CN (2) | CN100567288C (pt) |
AP (1) | AP2210A (pt) |
AR (1) | AR047008A1 (pt) |
AT (2) | ATE358674T1 (pt) |
AU (2) | AU2003294313B2 (pt) |
BR (1) | BR0316305A (pt) |
CA (1) | CA2506242C (pt) |
CO (1) | CO5690588A2 (pt) |
CR (2) | CR7877A (pt) |
CY (2) | CY1107682T1 (pt) |
DE (2) | DE60322451D1 (pt) |
DK (2) | DK1803718T3 (pt) |
EA (1) | EA008621B1 (pt) |
EC (1) | ECSP055840A (pt) |
ES (2) | ES2312150T3 (pt) |
GE (1) | GEP20084539B (pt) |
HK (1) | HK1086829A1 (pt) |
IL (1) | IL209352A0 (pt) |
IS (2) | IS2720B (pt) |
MA (1) | MA27565A1 (pt) |
ME (1) | MEP48108A (pt) |
MX (1) | MXPA05004669A (pt) |
MY (1) | MY135647A (pt) |
NI (1) | NI200500087A (pt) |
NO (1) | NO20052894L (pt) |
NZ (2) | NZ572685A (pt) |
OA (1) | OA13010A (pt) |
PT (2) | PT1803718E (pt) |
RS (1) | RS51047B (pt) |
SG (1) | SG165998A1 (pt) |
SI (2) | SI1562932T1 (pt) |
TW (2) | TWI343917B (pt) |
WO (1) | WO2004046132A1 (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7202259B2 (en) * | 2002-11-18 | 2007-04-10 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
US8790689B2 (en) * | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
AR047936A1 (es) | 2003-04-30 | 2006-03-15 | Purdue Pharma Ltd | Forma de dosificacion transdermica resistente a la manipulacion |
EP2277875A3 (en) | 2004-01-30 | 2011-04-20 | Euro-Celtique S.A. | Methods for making 4-tetrazolyl-4-phenylpiperidine compounds |
SE0401656D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
CN101312964A (zh) * | 2005-11-21 | 2008-11-26 | 普渡制药公司 | 4-噁二唑基哌啶化合物及其用途 |
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
WO2011056561A1 (en) | 2009-10-27 | 2011-05-12 | Beth Israel Deaconess Medical Center | Methods and compositions for the generation and use of conformation-specific antibodies |
CA2810356C (en) | 2010-09-21 | 2016-06-14 | Purdue Pharma L.P. | Buprenorphine analogs |
CN102648915B (zh) * | 2011-02-28 | 2015-04-15 | 鲁南制药集团股份有限公司 | 一种治疗或预防神经病理性疼痛的药物组合物 |
US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
EP2917182B1 (en) | 2012-11-09 | 2018-01-03 | Purdue Pharma LP | Benzomorphan analogs and the use thereof |
WO2014087226A1 (en) | 2012-12-07 | 2014-06-12 | Purdue Pharma L.P. | Buprenorphine analogs as opiod receptor modulators |
ES2621305T3 (es) | 2012-12-14 | 2017-07-03 | Purdue Pharma Lp | Morfinanos espirocíclicos y su uso |
WO2014091295A1 (en) | 2012-12-14 | 2014-06-19 | Purdue Pharma L.P. | Pyridonemorphinan analogs and biological activity on opioid receptors |
EP2951160B1 (en) | 2013-01-31 | 2019-04-24 | Purdue Pharma LP | Benzomorphan analogs and the use thereof |
US8969358B2 (en) | 2013-03-15 | 2015-03-03 | Purdue Pharma L.P. | Buprenorphine analogs |
EP3087057A4 (en) | 2013-12-26 | 2017-06-28 | Purdue Pharma LP | Ring-contracted morphinans and the use thereof |
US9994571B2 (en) | 2013-12-26 | 2018-06-12 | Purdue Pharma L.P. | 10-substituted morphinan hydantoins |
EP3087079B1 (en) | 2013-12-26 | 2019-04-03 | Purdue Pharma LP | Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans |
WO2015097546A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | Propellane-based compounds and their use as opioid receptor modulators |
WO2015097548A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | 7-beta-alkyl analogs of orvinols |
WO2015099863A1 (en) | 2013-12-27 | 2015-07-02 | Purdue Pharma L.P. | 6-substituted and 7-substituted morphinan analogs and the use thereof |
CA2950567A1 (en) | 2014-05-27 | 2015-12-03 | Purdue Pharma L.P. | Spirocyclic morphinans and use thereof |
JP6360915B2 (ja) | 2014-06-13 | 2018-07-18 | パーデュー、ファーマ、リミテッド、パートナーシップ | アザモルフィナン誘導体及びその使用 |
MA41125A (fr) | 2014-12-05 | 2017-10-10 | Purdue Pharma Lp | Dérivés de 6.7-cyclomorphinane et leur utilisation |
WO2017165558A1 (en) | 2016-03-22 | 2017-09-28 | Regents Of The University Of Minnesota | Combination for treating pain |
WO2018125716A1 (en) | 2017-01-02 | 2018-07-05 | Purdue Pharma L.P. | Morphinan derivatives and use thereof |
BR112023023702A2 (pt) * | 2021-05-21 | 2024-01-30 | Purdue Pharma Lp | Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga |
WO2023250190A1 (en) * | 2022-06-24 | 2023-12-28 | Purdue Pharma L.P. | Methods of treating or preventing overactive bladder syndrome |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3598122A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
BE775611A (fr) | 1970-11-24 | 1972-03-16 | Synthelabo | Derives de la (diphenyl-3,3 propyl-1)-1 piperidine, leur preparation etles medicaments qui en contiennent |
US4076717A (en) * | 1971-12-15 | 1978-02-28 | G. D. Searle & Co. | Derivatives of 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
DK162087D0 (da) * | 1987-03-31 | 1987-03-31 | Ferrosan As | Piperidinforbindelser, deres fremstilling og anvendelse |
US4831192A (en) * | 1987-12-31 | 1989-05-16 | Boc, Inc. | Methods of preparing 4-heteropentacyclic-4-(N-phenyl)amido) piperidine derivatives and intermediate compounds |
US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5698155A (en) * | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5449989A (en) | 1992-07-31 | 1995-09-12 | Correa; Paulo N. | Energy conversion system |
US5736523A (en) | 1992-11-09 | 1998-04-07 | Biochem Pharma Inc. | Antineoplastic heteronapthoquinones |
US5606037A (en) | 1992-11-09 | 1997-02-25 | Biochem Pharma Inc. | Processes antineoplastic heteronaphthoquinones |
US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5849737A (en) | 1995-04-14 | 1998-12-15 | The Regents Of The University Of California | Compositions and methods for treating pain |
US6166085A (en) | 1995-04-14 | 2000-12-26 | The Regents Of The University Of California | Method of producing analgesia |
ATE301457T1 (de) * | 1995-06-12 | 2005-08-15 | Searle & Co | Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor |
US5849761A (en) | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
US6573282B1 (en) | 1995-09-12 | 2003-06-03 | Adolor Corporation | Peripherally active anti-hyperalgesic opiates |
AU1208397A (en) | 1995-12-28 | 1997-07-28 | Takeda Chemical Industries Ltd. | Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists |
US6221888B1 (en) | 1997-05-29 | 2001-04-24 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
PL188450B1 (pl) * | 1997-06-10 | 2005-02-28 | Synthon Bv | Pochodne 4-fenylopiperydyny, sposób wytwarzania pochodnych 4-fenylopiperydyny, zastosowanie pochodnej 4-fenylopiperydyny oraz środek farmaceutyczny |
CN1291984A (zh) | 1998-03-06 | 2001-04-18 | 詹森药业有限公司 | 甘氨酸传输抑制剂 |
US6423519B1 (en) * | 1998-07-15 | 2002-07-23 | Gpc Biotech Inc. | Compositions and methods for inhibiting fungal growth |
PE20001420A1 (es) | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
US7217714B1 (en) | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
IL144897A0 (en) | 1999-03-12 | 2002-06-30 | Boehringer Ingelheim Pharma | Compounds useful as anti-inflammatory agents |
CA2383147A1 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Mch antagonists |
CA2324330A1 (en) | 1999-11-08 | 2001-05-08 | Ssp Co., Ltd. | 4-hydroxy-4-phenylpiperidine derivatives and pharmaceuticals containing the same |
EP1242085B1 (en) | 1999-12-06 | 2005-08-24 | Euro-Celtique, S.A. | Benzimidazole compounds having nociceptin receptor affinity |
EP1244678A1 (en) | 1999-12-22 | 2002-10-02 | Merck Frosst Canada Inc. | Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
US6703525B2 (en) | 2000-02-16 | 2004-03-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Sulfonamide intermediates and methods of producing same |
US6608052B2 (en) | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
EP1277737A4 (en) | 2000-03-24 | 2003-05-07 | Meiji Seika Kaisha | DIPHENYLALKYLAMINE DERIVATIVES AS AGONISTS OF THE OPIOID -g (d) RECEPTOR |
US6544981B2 (en) | 2000-06-09 | 2003-04-08 | Bristol-Myers Squibb Company | Lactam inhibitors of factor Xa and method |
WO2002030896A1 (fr) | 2000-10-12 | 2002-04-18 | Ssp Co., Ltd. | Derives 2,2-diphenylbutanamide et agents pharmaceutiques contenant ces composes |
WO2002038185A2 (en) | 2000-11-13 | 2002-05-16 | Atrix Laboratories, Inc. | Injectable sustained release delivery system with loperamide |
US7202259B2 (en) * | 2002-11-18 | 2007-04-10 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
EP2277875A3 (en) * | 2004-01-30 | 2011-04-20 | Euro-Celtique S.A. | Methods for making 4-tetrazolyl-4-phenylpiperidine compounds |
-
2003
- 2003-11-13 US US10/714,066 patent/US7202259B2/en active Active
- 2003-11-17 JP JP2004570427A patent/JP4601429B2/ja not_active Expired - Fee Related
- 2003-11-17 ES ES07006697T patent/ES2312150T3/es not_active Expired - Lifetime
- 2003-11-17 WO PCT/US2003/036742 patent/WO2004046132A1/en active Search and Examination
- 2003-11-17 DE DE60322451T patent/DE60322451D1/de not_active Expired - Lifetime
- 2003-11-17 NZ NZ572685A patent/NZ572685A/en not_active IP Right Cessation
- 2003-11-17 CA CA2506242A patent/CA2506242C/en not_active Expired - Fee Related
- 2003-11-17 ES ES03789796T patent/ES2285235T3/es not_active Expired - Lifetime
- 2003-11-17 CN CNB2003801035027A patent/CN100567288C/zh not_active Expired - Fee Related
- 2003-11-17 OA OA1200500145A patent/OA13010A/en unknown
- 2003-11-17 MX MXPA05004669A patent/MXPA05004669A/es active IP Right Grant
- 2003-11-17 ME MEP-481/08A patent/MEP48108A/xx unknown
- 2003-11-17 AU AU2003294313A patent/AU2003294313B2/en not_active Ceased
- 2003-11-17 RS YUP-2005/0375A patent/RS51047B/sr unknown
- 2003-11-17 SI SI200330814T patent/SI1562932T1/sl unknown
- 2003-11-17 BR BR0316305-9A patent/BR0316305A/pt not_active IP Right Cessation
- 2003-11-17 PT PT07006697T patent/PT1803718E/pt unknown
- 2003-11-17 EP EP03789796A patent/EP1562932B9/en not_active Expired - Lifetime
- 2003-11-17 DK DK07006697T patent/DK1803718T3/da active
- 2003-11-17 NZ NZ540068A patent/NZ540068A/en not_active IP Right Cessation
- 2003-11-17 GE GEAP20038846A patent/GEP20084539B/en unknown
- 2003-11-17 AT AT03789796T patent/ATE358674T1/de active
- 2003-11-17 EP EP07006697A patent/EP1803718B1/en not_active Expired - Lifetime
- 2003-11-17 AP AP2005003297A patent/AP2210A/xx active
- 2003-11-17 DE DE60313021T patent/DE60313021T2/de not_active Expired - Lifetime
- 2003-11-17 CN CN200910173679A patent/CN101648941A/zh active Pending
- 2003-11-17 EA EA200500726A patent/EA008621B1/ru not_active IP Right Cessation
- 2003-11-17 SI SI200331358T patent/SI1803718T1/sl unknown
- 2003-11-17 DK DK03789796T patent/DK1562932T3/da active
- 2003-11-17 SG SG200703631-2A patent/SG165998A1/en unknown
- 2003-11-17 KR KR1020057008903A patent/KR20050115221A/ko active IP Right Grant
- 2003-11-17 AT AT07006697T patent/ATE402167T1/de active
- 2003-11-17 PT PT03789796T patent/PT1562932E/pt unknown
- 2003-11-18 MY MYPI20034402A patent/MY135647A/en unknown
- 2003-11-18 TW TW092132303A patent/TWI343917B/zh not_active IP Right Cessation
- 2003-11-18 TW TW096151468A patent/TW200819436A/zh unknown
- 2003-11-19 AR ARP030104269A patent/AR047008A1/es unknown
-
2005
- 2005-04-19 IS IS7812A patent/IS2720B/is unknown
- 2005-04-22 NI NI200500087A patent/NI200500087A/es unknown
- 2005-05-20 CO CO05048789A patent/CO5690588A2/es not_active Application Discontinuation
- 2005-06-07 EC EC2005005840A patent/ECSP055840A/es unknown
- 2005-06-13 MA MA28335A patent/MA27565A1/fr unknown
- 2005-06-14 NO NO20052894A patent/NO20052894L/no not_active Application Discontinuation
- 2005-06-16 CR CR7877A patent/CR7877A/es unknown
-
2006
- 2006-06-14 HK HK06106822.5A patent/HK1086829A1/xx not_active IP Right Cessation
-
2007
- 2007-03-28 US US11/729,660 patent/US7687518B2/en not_active Expired - Lifetime
- 2007-06-21 CY CY20071100825T patent/CY1107682T1/el unknown
-
2008
- 2008-10-16 CY CY20081101151T patent/CY1108422T1/el unknown
-
2009
- 2009-09-21 CR CR11037A patent/CR11037A/es not_active Application Discontinuation
- 2009-11-10 US US12/615,510 patent/US8026254B2/en not_active Expired - Lifetime
-
2010
- 2010-03-12 JP JP2010056560A patent/JP2010163452A/ja active Pending
- 2010-07-21 IS IS8913A patent/IS8913A/is unknown
- 2010-11-16 IL IL209352A patent/IL209352A0/en unknown
- 2010-11-25 AU AU2010246411A patent/AU2010246411A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0316305A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit | |
BRPI0411241A (pt) | agentes terapêuticos úteis para o tratamento de dor | |
CY1109031T1 (el) | Τριαζασπιρο ενωσεις χρησιμες για την αντιμετωπιση ή προληψη πονου | |
BR0314699A (pt) | Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula | |
BRPI0108977B8 (pt) | compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
BRPI0519195A2 (pt) | composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal | |
WO2005107726A3 (en) | Method for the treatment of back pain | |
BR0309343A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
MXPA06012500A (es) | Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo. | |
WO1992019617A3 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
MXPA05000765A (es) | Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos. | |
BRPI0417902A (pt) | piperazinas úteis no tratamento da dor | |
WO2005011590A3 (en) | Compositions and methods for restoring sensitivity to treatment with her2 antagonists | |
BR9915390A (pt) | Tratamento de tumores através de administração de compostos que liberam harmÈnio de crescimento e seus antagonistas | |
IL166596A0 (en) | Salt of morphine-6-glucoronide | |
BRPI0408500A (pt) | tratamento do diabetes do tipo 1 com inibidores de pde5 | |
BRPI0415546A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios | |
EA200500687A1 (ru) | Применение дистронциевой соли 2-[n,n-ди(карбоксиметил)амино]-3-циано-4-карбоксиметилтиофен-5-карбоновой кислоты при получении лекарственных средств, предназначенных для лечения гастродуоденальной боли | |
UA86009C2 (ru) | 4-тетразолил-4-фенилпиперидиновые производные для лечения боли | |
BR0113886A (pt) | Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit | |
TNSN05114A1 (en) | 4-tetrazolyl -4 phenylpiperidine derivatives for treating pain | |
WO2005035500A3 (en) | Therapeutic agents useful for treating pain | |
BRPI0409868A (pt) | composição farmacêutica que compreende um inibidor da catepsina s e um opióide | |
UA4486U (uk) | Препарат "глютам-1м" для стимуляції запліднюваності самок тварин | |
TW200510348A (en) | 5-aryltetrazole compounds, compositions thereof, and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES. |
|
B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |